A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
PHASE2
This phase 2b study will evaluate the efficacy and safety of 16 and 24 week...
A Study of Sustained Virological Response in Relation to IL28-b Expression in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1 on Combination Treatment With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)
PHASE4
This multi-center, open-label study will evaluate the efficacy and safety o...
An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Copegus (Ribavirin) in Participants With Chronic Hepatitis C (CHC), Genotype 2, 3, 1 or 4, Undergoing Opioid Maintenance Therapy
N/A
This prospective, multi-center, observational study will evaluate the effic...
Status
Completed
Location
Lkh Hoergas-Enzenbach; Abt. Für Innere Medizin
Start Date
2010-04
Trial ID
NCT01416610
An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus
PHASE1
The purpose of this study is to assess the safety, efficacy, and pharmacoki...
Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1.
PHASE4
This single arm study will evaluate the efficacy and safety of PEGASYS (180...
PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b
N/A
This observational study will assess predictors of early on-treatment and s...